Authors

• Renata Ferrarotto (ORCID: https://orcid.org/0000-0002-3561-215X)
• Caroline Even (ORCID: https://orcid.org/0000-0002-8493-7444)
• Bohuslav Melichar (ORCID: https://orcid.org/0000-0002-5474-6866)
• Leon Hooftman
• Erminia Massarelli (ORCID: https://orcid.org/0000-0001-7798-7286)
• Jérôme Fayette (ORCID: https://orcid.org/0000-0002-8126-7019)
• Cornelis J.M. Melief (ORCID: https://orcid.org/0000-0001-5709-3584)
• Sonja Visscher (ORCID: https://orcid.org/0000-0001-9815-059X)
• Lisa Francesca Licitra (ORCID: https://orcid.org/0000-0003-0623-4118)
• Marc Oliva (ORCID: https://orcid.org/0000-0001-5352-8130)
• Simon Laban (ORCID: https://orcid.org/0000-0001-6732-7137)
• Anthony Kong (ORCID: https://orcid.org/0000-0002-3989-3948)
• Matthew G. Fury
• Kevin Joseph Harrington (ORCID: https://orcid.org/0000-0002-6014-348X)
• Irene Braña (ORCID: https://orcid.org/0000-0002-1068-9601)
• Anna‐Sophia Wiekmeijer (ORCID: https://orcid.org/0000-0001-9919-0446)
• Lot A. Devriese (ORCID: https://orcid.org/0009-0009-9324-7814)
• Marshall R. Posner (ORCID: https://orcid.org/0000-0003-1912-3281)
• Marielle Klein Hesselink
• Bonnie S. Glisson
• Petra Jankowska

Institutions

• City Of Hope National Medical Center (US)
• Mount Sinai Health System (US)
• The University of Texas MD Anderson Cancer Center (US)
• Institute of Cancer Research (GB)
• King's College London (GB)
• Regeneron (United States) (US)
• Institut Gustave Roussy (FR)
• University Medical Center Utrecht (NL)
• Oxford Biotherapeutics (United Kingdom) (GB)
• Goudappel Coffeng (NL)
• Centre Léon Bérard (FR)
• Institut Català d'Oncologia (ES)
• LinXis Biopharmaceuticals (Netherlands) (NL)
• Taunton & Somerset NHS Foundation Trust (GB)
• Galapagos (Netherlands) (NL)
• University Hospital Ulm (DE)
• Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
• Astellas Pharma (Netherlands) (NL)
• Vall d'Hebron Institute of Oncology (ES)
• Palacký University Olomouc (CZ)

Publication Details

Journal

Journal for ImmunoTherapy of Cancer

Published

2025-09-01

DOI

https://doi.org/10.1136/jitc-2025-012555

Citations

2

Primary Topic

Cancer Immunotherapy and Biomarkers

Type

article

Field-Weighted Citation Impact

2.09

Funders

• Regeneron Pharmaceuticals